Australia grants provisional registration for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Up to 100 million mRNA vaccine doses could be produced in Australia each year
It is a novel oral NLRP3 inflammasome inhibitor
The company plans to expand its portfolio in regulated markets aggressively
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
Subscribe To Our Newsletter & Stay Updated